168 related articles for article (PubMed ID: 27279143)
1. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
Suzuki S; Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Suda T
Invest New Drugs; 2016 Aug; 34(4):490-6. PubMed ID: 27279143
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Yokoi T; Minami S; Shiroyama T; Koba T; Torii Y; Sugimoto H; Niki M; Mori M; Morimura O; Hirashima T; Komuta K; Kijima T
Intern Med; 2019 May; 58(10):1405-1410. PubMed ID: 30713297
[TBL] [Abstract][Full Text] [Related]
3. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
Tanaka K; Morita S; Ando M; Yokoyama T; Nakamura A; Yoshioka H; Ishiguro T; Miura S; Toyozawa R; Oguri T; Daga H; Ko R; Bessho A; Tachihara M; Iwamoto Y; Hirano K; Nakanishi Y; Nakagawa K; Yamamoto N; Okamoto I
Cancer; 2020 Aug; 126(16):3648-3656. PubMed ID: 32484914
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
9. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Yoshioka H; Okamoto I; Morita S; Ando M; Takeda K; Seto T; Yamamoto N; Saka H; Atagi S; Hirashima T; Kudoh S; Satouchi M; Ikeda N; Iwamoto Y; Sawa T; Nakanishi Y; Nakagawa K
Ann Oncol; 2013 May; 24(5):1326-31. PubMed ID: 23277482
[TBL] [Abstract][Full Text] [Related]
11. Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
Komazaki Y; Sakashita H; Furuiye M; Fujie T; Tamaoka M; Sumi Y; Miyazaki Y; Kojima K; Jin Y; Inase N
Chemotherapy; 2013; 59(1):35-41. PubMed ID: 23816760
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Wang T; Zhang SF; Qiu MQ; Li QL
Cancer Radiother; 2016 May; 20(3):181-6. PubMed ID: 27068497
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Imai H; Utsugi M; Iwasaki Y; Shimizu K; Iijima H; Tsurumaki H; Tomizawa Y; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 May; 68(2):253-7. PubMed ID: 19631403
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]